Corvus reports Q2 net loss $6.5M, soquelitinib shows 3 CR/3 PR in TCL; plans FDA meeting

Corvus Pharmaceuticals, Inc.

2023-Q2 EPS reported -$0.31

Soquelitinib Phase 1/1b: 3 complete, 3 partial responses in 20 evaluable TCL patients.
ALC >900/mL: 6/14 objective responses; 0/6 below 900. FDA meeting for Phase 3 in Q3.
Cash $37.0M as of June 30, 2023; projected $28-30M year-end, funding into H2 2024.
Q2 R&D expense $4.0M (down from $4.9M); net loss $6.5M vs $8.4M in Q2 2022.
Ciforadenant Phase 1b/2 in RCC initial data expected year-end 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Corvus Pharmaceuticals, Inc. reported financial results for the second quarter ended June 30, 2023.

Period: the second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the second quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

Corvus Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-23-005102

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.